HOME >> MEDICINE >> NEWS
A site for sore eyes: New target for allergies found under the eyelid

Scientists have found a protein in the eye which plays a critical role in how an allergic response develops over a 24-hour period. The University College London (UCL) team hope their discovery will pave the way for new treatments for allergic diseases such as asthma, eczema and hay fever.

In a study published today in the online edition of the Journal of Clinical Investigation, Professor Santa Jeremy Ono and colleagues from UCL's Institute of Ophthalmology and Moorfields Eye Hospital found that the macrophage inflammatory protein-1a, known as MIP-1a and located in the eye, plays a crucial role in the early stages of an allergic response. Their findings suggest that drugs that block the binding of MIP-1a to its receptors could help in the treatment of ocular allergy and other allergic diseases.

Allergies affect over one third of individuals in the Western world, with 17 million people in the UK currently suffering from asthma, conjunctivitis, eczema or hay fever.

Allergic responses develop in two phases. The first phase involves an immediate hypersensitivity reaction within one hour of exposure to an allergen, where mast cells (key cells responsible for causing allergies) release histamine and other molecules such as chemokines. MIP-1a is one such chemokine.

The second phase, which occurs 12 to 24 hours after exposure, involves the recruitment of inflammatory cells to the site of inflammation. While the role of chemokines in the second phase is well characterized, little is known about how chemokines contribute to the first phase of an allergic disease.

Ono and colleagues discovered that within the clear membrane that coats the inner surface of the eyelid and outer surface of the eye, known as the conjunctiva, MIP-1a was essential in the initial stages of development of an allergic response.

MIP-1a was also necessary for the second phase of the disease, which is associated with chronic allergy. It is likely t
'"/>

Contact: Jenny Gimpel
j.gimpel@ucl.ac.uk
44-207-679-9739
University College London
13-Jan-2005


Page: 1 2

Related medicine news :

1. Kaleidescope eyes: the secrets of a novel gift
2. NHS target driven culture is failing patients
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. NHS stop-smoking services are insufficient to deliver national smoking targets
5. Tumor-targeted immune cells cure prostate cancer in mice without causing systemic immune suppression
6. Potential drug target for treating cocaine abuse found
7. NHS Trusts meeting government target on stroke units in name only
8. Inflammatory cells highly promising target in NF 1
9. T cells target HIV in a relationship on the rebound
10. Residual tumor cells are a barrier to targeted cancer therapeutics
11. Genetically targeted therapies create opportunities to do business in new ways

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes ... a mock evacuation of the facility as part of a disaster drill on October ... Hose EMS and Shelton City Emergency Manager, as well as the Connecticut Long ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
Breaking Medicine Technology:
Cached News: